$ARWR Arrowhead Pharmaceuticals, Inc. Just Missed Earnings And Its EPS Looked Sad - But Analysts Have Updated Their Models finance.yahoo.com/news/arro... Good read ! It will come as a surprise to learn that the consensus price target rose 26% to US$56.86, with analysts clearly more interested in growing revenue, even as losses intensify. The consensus price target just an average of individual analyst targets, so - considering that the price target changed, it would be handy to see how wide the range of underlying estimates is. Currently, the most bullish analyst values Arrowhead Pharmaceuticals at US$72.00 per share, while the most bearish prices it at US$36.00. This is a fairly broad spread of estimates, suggesting that analysts are forecasting a wide range of possible outcomes for the business. $IBB $XBI $XLV
  • 7
  • 2